| Literature DB >> 33472007 |
Laura E Toles1,2, Andrew J Ortiz1, Katherine L Marks1,2, James A Burns1,3, Tiffiny Hron1,3, Jarrad H Van Stan1,2,3, Daryush D Mehta1,2,3, Robert E Hillman1,2,3.
Abstract
Purpose Previous ambulatory voice monitoring studies have included many singers and have combined speech and singing in the analyses. This study applied a singing classifier to the ambulatory recordings of singers with phonotrauma and healthy controls to determine if analyzing speech and singing separately would reveal voice use differences that could provide new insights into the etiology and pathophysiology of phonotrauma in this at-risk population. Method Forty-two female singers with phonotrauma (vocal fold nodules or polyps) and 42 healthy matched controls were monitored using an ambulatory voice monitor. Weeklong statistics (average, standard deviation, skewness, kurtosis) for sound pressure level (SPL), fundamental frequency, cepstral peak prominence, the magnitude ratio of the first two harmonics (H1-H2 ), and three vocal dose measures were computed from the neck surface acceleration signal and separated into singing and speech using a singing classifier. Results Mixed analysis of variance models found expected differences between singing and speech in each voice parameter, except SPL kurtosis. SPL skewness, SPL kurtosis, and all H1-H2 distributional parameters differentiated patients and controls when singing and speech were combined. Interaction effects were found in H1-H2 kurtosis and all vocal dose measures. Patients had significantly higher vocal doses in speech compared to controls. Conclusions Consistent with prior work, the pathophysiology of phonotrauma in singers is characterized by more abrupt/complete glottal closure (decreased mean and variation for H1-H2 ) and increased laryngeal forces (negatively skewed SPL distribution) during phonation. Application of a singing classifier to weeklong data revealed that singers with phonotrauma spent more time speaking on a weekly basis, but not more time singing, compared to controls. Results are used as a basis for hypothesizing about the role of speaking voice in the etiology of phonotraumatic vocal hyperfunction in singers.Entities:
Mesh:
Year: 2021 PMID: 33472007 PMCID: PMC8740583 DOI: 10.1044/2020_AJSLP-20-00227
Source DB: PubMed Journal: Am J Speech Lang Pathol ISSN: 1058-0360 Impact factor: 2.408
Patients' self-reported impact on quality of life due to their voice disorder using the Voice-Related Quality of Life (V-RQOL) subscales and the perceived voice quality judged by a speech-language pathologist using the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) form.
| Measure |
|
|---|---|
| CAPE-V | |
| Overall Severity | 22.8 (11.9) |
| Roughness | 16.2 (12.9) |
| Breathiness | 12.5 (12.9) |
| Strain | 18.0 (9.9) |
| Pitch | 4.2 (7.9) |
| Loudness | 4.5 (9.2) |
| V-RQOL | |
| Social–Emotional | 68.5 (23.0) |
| Physical Functioning | 73.3 (18.3) |
| Total score | 71.5 (17.8) |
Note. Mean and standard deviation reported for each subscale measure. The CAPE-V was administered for the total patient cohort (n = 42). V-RQOL scores were available for 40 patients.
Main effects of phonation type (singing or speech) are presented with means (standard deviations) of the weekly summary statistics of sound pressure level (SPL), fundamental frequency (f 0), cepstral peak prominence (CPP), the difference between the first two harmonics (H), and vocal dose measures for combined participant groups (patients and controls) in singing and speech separately.
| Variable | Main effect | Cohen's | Singing | Speech |
|---|---|---|---|---|
| SPL | ||||
| | < .0001 | 0.80 | 88.78 (5.99) | 84.43 (4.76) |
| | < .0001 | 0.32 | 12.47 (2.63) | 11.70 (2.12) |
| Skewness | < .0001 | 0.49 | −0.31 (0.37) | −0.15 (0.28) |
| Kurtosis | .1196 | — | 3.23 (0.70) | 3.12 (0.35) |
|
| ||||
| Mode (Hz) | < .0001 | 2.27 | 319.86 (42.95) | 199.62 (19.17) |
| | < .0001 | 2.91 | 95.36 (14.24) | 61.23 (8.54) |
| Skewness | < .0001 | 2.84 | 1.12 (0.35) | 2.25 (0.44) |
| Kurtosis | < .0001 | 2.49 | 5.16 (1.60) | 12.30 (3.73) |
| CPP | ||||
| | < .0001 | 1.00 | 21.82 (1.51) | 23.15 (1.12) |
| | < .0001 | 1.56 | 3.97 (0.36) | 4.51 (0.33) |
| Skewness | < .0001 | 1.15 | −0.03 (0.30) | −0.31 (0.17) |
| Kurtosis | < .0001 | 0.79 | 2.60 (0.30) | 2.41 (0.16) |
|
| ||||
| | < .0001 | 2.34 | 9.05 (2.33) | 4.03 (1.95) |
| | < .0001 | 1.29 | 7.31 (0.81) | 6.29 (0.77) |
| Skewness | .0001 | 0.24 | 0.55 (0.25) | 0.69 (0.77) |
| Kurtosis | < .0001 | 1.42 | 3.07 (0.52) | 3.97 (0.73) |
| Dose | ||||
| Phonation time (%) | < .0001 | 2.91 | 2.32 (1.19) | 7.14 (2.02) |
| Cycle dose (cycles/hr) | < .0001 | 1.70 | 31,002 (16,950) | 59,442 (16,420) |
| Distance dose (m/hr) | < .0001 | 1.59 | 118.58 (67.50) | 240.48 (85.20) |
Significance at or below corrected α value (SPL, f 0, CPP, and H α = .0125; Dose α = .0166).
Interactions and main effects of diagnosis (patient or control) are presented with group-based means (standard deviations) of the weekly summary statistics of sound pressure level (SPL), fundamental frequency (f 0), cepstral peak prominence (CPP), the difference between the first two harmonics (H), and vocal dose measures for combined phonation type (singing or speech).
| Variable | Interaction | Diagnosis main effect | Cohen's | Patient | Control |
|---|---|---|---|---|---|
| SPL | |||||
| | .1349 | .0695 | — | 86.12 (4.23) | 85.03 (5.07) |
| | .1034 | .0723 | — | 11.69 (1.96) | 12.61 (2.49) |
| Skewness | .1447 | < .0001 | 0.87 | −0.26 (0.24) | −0.04 (0.25) |
| Kurtosis | .0498 | .0020 | 0.60 | 3.19 (0.34) | 2.94 (0.34) |
|
| |||||
| Mode (Hz) | .0363 | .0786 | — | 201.34 (20.41) | 202.67 (17.95) |
| | .6692 | .0212 | — | 82.94 (12.62) | 98.04 (18.07) |
| Skewness | .0666 | .3359 | — | 1.84 (0.45) | 1.51 (0.43) |
| Kurtosis | .4127 | .6110 | — | 8.22 (3.22) | 6.15 (2.11) |
| CPP | |||||
| | .0618 | .0193 | — | 23.15 (0.99) | 22.52 (1.26) |
| | .5197 | .1400 | — | 4.48 (0.26) | 4.38 (0.37) |
| Skewness | .1077 | .0253 | — | −0.27 (0.16) | −0.17 (0.18) |
| Kurtosis | .6150 | .8223 | — | 2.41 (0.14) | 2.38 (0.18) |
|
| |||||
| | .0222 | .0001 | 0.49 | 4.40 (1.69) | 6.19 (1.98) |
| | .0546 | .0009 | 0.52 | 6.45 (0.78) | 7.34 (0.95) |
| Skewness | .4764 | .0018 | 0.49 | 0.77 (0.24) | 0.62 (0.21) |
| Kurtosis | .0013 | < .0001 | 0.71 | 4.15 (0.68) | 3.38 (0.57) |
| Dose | |||||
| Phonation time (%) | < .0001 | .0523 | — | 9.92 (2.31) | 8.93 (2.55) |
| Cycle dose (cycles/hr) | < .0001 | .6400 | — | 90,745 (20,261) | 89,083 (28,634) |
| Distance dose (m/hr) | < .0001 | .3205 | — | 370.46 (103.84) | 345.71 (134.28) |
Note. Means and standard deviations are presented for each group with singing and speech combined.
Significance at or below corrected α value (f 0, SPL, CPP, and H α = .0125; Dose α = .0166).
Group-based means (standard deviations), significance values, and effect sizes of weekly summary statistics for the voice parameters that showed significant interaction effects (diagnosis by phonation type) during the mixed analysis of variance, presented separately for each phonation type (singing and speech).
| Variable | Speech | Singing | ||||||
|---|---|---|---|---|---|---|---|---|
| Patient | Control |
| Cohen's | Patient | Control |
| Cohen's | |
|
| ||||||||
| Kurtosis | 4.35 (0.73) | 3.58 (0.49) | < .0001 | 0.88 | 3.20 (0.55) | 2.94 (0.45) | .0252 | — |
| Dose | ||||||||
| Phonation time (%) | 7.96 (1.94) | 6.32 (1.77) | < .0001 | 0.67 | 2.02 (0.91) | 2.63 (1.77) | .0262 | — |
| Cycle dose (cycles/hr) | 65,620 (14,632) | 53,264 (15,922) | .0002 | 0.61 | 26,073 (11,994) | 37,930 (19,697) | .0098 | — |
| Distance dose (m/hr) | 268.30 (75.31) | 212.67 (86.25) | .0010 | 0.54 | 103.73 (51.30) | 133.43 (78.35) | .0498 | — |
Significance at or below corrected α value (H α = .025; Dose α = .0083).